HPgV-2 Nucleic Acid Detection Probes and Primers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective detection and treatment strategies for human Pegivirus 2 (HPgV-2), a virus distinct from HPgV-1, which has not been clearly associated with disease but may influence the progression of other infections like HIV, and there is a need for specific nucleic acid probes, primers, and immunogenic compositions to detect and manage HPgV-2 infections.
Innovation Solution
Development of HPgV-2 specific nucleic acid probes and primers for detecting nucleic acid, and immunogenic compositions comprising synthetic nucleic acid molecules and peptides for treating subjects, including recombinant peptides with high identity to HPgV-2 sequences, to facilitate detection and immune response generation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If general flavivirus detection methods are used, then broad virus detection capability is achieved, but detection precision for HPgV-2 is insufficient
Solution Approach 1:
The patent segments the detection approach by developing HPgV-2 specific nucleic acid probes and primers that target unique regions of the HPgV-2 genome, distinguishing it from other flaviviruses while maintaining the ability to detect HPgV-2 specifically
Solution Approach 2:
The invention applies local quality by designing detection reagents with specific sequences that hybridize to unique HPgV-2 genomic regions, providing localized specific detection capability within the broader flavivirus detection framework
2Measurement precision
If HPgV-1 detection methods are used, then HPgV-1 detection is achieved, but HPgV-2 detection fails due to sequence divergence
Solution Approach 1:
The patent creates separate detection systems for HPgV-1 and HPgV-2, with distinct nucleic acid probes and primers designed to recognize sequence-specific differences between the two viruses, ensuring accurate differentiation
Solution Approach 2:
The invention changes the detection parameters by developing new probes and primers with sequences optimized for HPgV-2, accounting for the sequence divergence between HPgV-1 and HPgV-2 to achieve specific detection
3Reliability
If no specific treatment strategies are developed, then resource allocation is maintained, but disease progression control is insufficient
Solution Approach 1:
The patent prepares immunogenic compositions in advance that can stimulate immune responses against HPgV-2, providing a ready-to-use treatment approach that can be deployed when infection is detected
Solution Approach 2:
The invention uses immunogenic compositions as intermediaries to bridge the gap between HPgV-2 infection and immune system activation, providing a mechanism for treatment that can be manufactured and administered
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate detection of HPgV-2 nucleic acid and specific immune responses, potentially influencing the progression of co-infections like HIV, providing a means to manage HPgV-2 infections effectively.
Implementation Method 1
comprising a nucleotide sequence that hybridizes under stringent conditions to a nucleic acid sequence of human Pegivirus 2 (HPgV-2)
Implementation Method 2
immunogenic compositions comprising synthetic nucleic acid molecules and peptides for treating subjects, including recombinant peptides with high identity to HPgV-2 sequences
Data Source
AI summary
Provided herein are compositions, methods, and kits for detecting human Pegivirus 2 (HPgV-2). In certain embodiments, provided herein are HPgV-2 specific nucleic acid probes and primers, and methods for detecting HPgV-2 nucleic acid. In other embodiments, provided herein are HPgV-2 immunogenic composition compositions, methods of treating a subject with immunogenic HPgV-2 peptides, and methods of detecting HPgV-2 subject antibodies in a sample.